Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 20 Neoplasms 19 Lung Neoplasms 11 Carcinoma, Non-Small-Cell Lung 8 Colorectal Neoplasms 6 Uterine Cervical Neoplasms 5 Prostatic Neoplasms 5 Pancreatic Neoplasms 5 Melanoma 5 Carcinoma, Hepatocellular 5 Brain Neoplasms 5 Skin Neoplasms 4 Ovarian Neoplasms 4 Myelodysplastic Syndromes 4 Leukemia, Myeloid, Acute 4 Triple Negative Breast Neoplasms 3 Neoplasm Metastasis 3 Myeloproliferative Disorders 3 Kidney Neoplasms 3 Head and Neck Neoplasms 3 Esophageal Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Renal Cell 3 Uveal Melanoma 2 Recurrence 2 Neoplasm, Residual 2 Lymphoma, Non-Hodgkin 2 Lymphoma, B-Cell 2 Lung Diseases 2 Glioma 2

Interventions

pertuzumab 5 Trastuzumab 5 Docetaxel 3 tucatinib 2 pyrotinib 1 atezolizumab 1 Paclitaxel 1 Neoadjuvant Therapy 1 Injections 1 Genetic Testing 1 Carboplatin 1 Capecitabine 1 Blood Specimen Collection 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × Blood Specimen Collection × 90 days × Clear all

NCT04638725 2026-06-04

SIGHER

Centre Paul Strauss

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡